Aldosterone mediates cardiac fibrosis in the setting of hypertension

Current Hypertension Reports

Volumn 15, Issue 4, 2013, Pages 395-400

  Azibani, Feriel ^a   Fazal, Loubina ^a   Chatziantoniou, Christos ^b   Samuel, Jane Lise ^a,c   Delcayre, Claude ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Aldosterone; AngII; Angiotensin II; Arterial hypertension; BNP; Cardiac remodeling; Fibrosis; Galectin 3; Mineralocorticoid receptor; MR; Myocardium; RAAS; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BRAIN NATRIURETIC PEPTIDE; CD68 ANTIGEN; GALECTIN 3; MINERALOCORTICOID RECEPTOR; PROCOLLAGEN C PROTEINASE; TRANSFORMING GROWTH FACTOR BETA1;

ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR MORTALITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FIBROBLAST; HEART MUSCLE; HEART MUSCLE FIBROSIS; HORMONAL REGULATION; HORMONE DETERMINATION; HUMAN; HYPERTENSION; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; ANIMALS; FIBROSIS; HEART DISEASES; HUMANS; HYPERTENSION;

EID: 84880925011     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0354-3     Document Type: Article

References (57)

1. Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension. 2012;59:367-74.
2. Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006;7:3-14.
3. Tait SA, Tait JF, Coghlan JP. The discovery, isolation and identification of aldosterone: reflections on emerging regulation and function. Mol Cell Endocrinol. 2004;217:1-21.
4. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-97.
5. Gilbert KC, Brown NJ. Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes. 2010;17:199-204.
6. Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens. 2012;21:147-56.
7. Bois P, Selye H. 2-Methyl-9(alpha)-chlorocortisol, a new synthetic mineralocorticoid with unusually intense nephrotoxic actions. Can Med Assoc J. 1956;75:720-4.
8. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893-901.
9. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773-81.
10. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-75.
11. Robert V, Van Thiem N, Cheav SL, et al. Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension. 1994;24:30-6.
12. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest. 1994;93:2578-83.
13. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350:266-72.
14. •• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-17. This large clinical trial was the first demonstration of the efficacy of spironolactone in heart failure. The spectacular benefit of this old diuretic was unexpected, and it rejuvenated both the experimental research on MR antagonists and the interest of clinicians for this therapeutic class.
15. Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700-6.
16. Weber KT, Sun Y, Bhattacharya SK, et al. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol. 2013;10:15-26.
17. Choisy SC, Arberry LA, Hancox JC, James AF. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension. 2007;49:498-505.
18. He X, Gao X, Peng L, et al. Atrial fibrillation induces myocardial fibrosis through angiotensin II type 1 receptor-specific Arkadia-mediated downregulation of Smad7. Circ Res. 2011;108:164-75.
19. • Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-8. This study in hypertensive patients demonstrated a link between aldosterone and atrial fibrillation (a major risk of heart failure). It was already known that the atrial remodeling, namely the fibrosis, was a major cause of arrhythmias.
20. • Ouvrard-Pascaud A, Sainte-Marie Y, Benitah JP, et al. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025-33. An experimental study (the first using conditional MR overexpression) that demonstrated the critical role of the MR in triggering arrhythmias. This paper showed that fibrosis was not involved in this process: MR activation induces an electrical remodeling that is explained by changes of expression of ionic channels.
21. Milliez P, Gomes S, Champ-Rigot L, et al. Effects of spironolactone alone and in addition to a beta-blocker on myocardial histological and electrical remodeling in chronic severe failing rat hearts. J Cardiovasc Pharmacol. 2012;60:315-21.
22. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-21.
23. Wang Q, Usinger W, Nichols B, et al. Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair. 2011;4:4.
24. Lemarie CA, Paradis P, Schiffrin EL. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. J Mol Med (Berl). 2008;86:673-8.
25. • Lemarie CA, Simeone SM, Nikonova A, et al. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors. Circ Res. 2009;105:852-9. The interplay between AngII and aldosterone is important in the induction of cardiovascular fibrosis. This paper give clues on the signaling pathways involving these two hormones.
26. Rocha R, Martin-Berger CL, Yang P, et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143:4828-36.
27. Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004;109:2213-20.
28. Virdis A, Neves MF, Amiri F, et al. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-10.
29. Mazak I, Fiebeler A, Muller DN, et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-800.
30. de Boer RA, Voors AA, Muntendam P, et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009;11:811-7.
31. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121-8.
32. • Azibani F, Benard L, Schlossarek S, et al. Aldosterone inhibits anti-fibrotic factors in mouse hypertensive heart. Hypertension. 2012;59:1179-87. This paper presents cardiac fibrosis as the result of a balance between pro-fibrotic and anti-fibrotic factors. This war, triggered by the association of aldosterone and AngII, saw the victory of the profibrotic factors. But it emerges from this paper that aldosterone, not only blocked the action of the valiant BNP, but also used an unfair trick: to recruit macrophages to invade the heart!.
33. • Calvier L, Miana M, Reboul P, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013;33:67-75. Galectin-3 interacts with numerous ligands such as cell surface receptors (integrins) and ECM proteins (collagen, elastin, fibronectin). This paper shows that galectin-3 is required for inflammatory and fibrotic responses to aldosterone in vascular smooth muscle cells in vitro and in vivo.
34. Kavvadas P, Weis L, Abed AB, et al. Renin inhibition reverses renal disease in transgenic mice by shifting the balance between profibrotic and antifibrotic agents. Hypertension. 2013;61:901-7.
35. Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 2003;9:964-8.
36. Pregizer S, Mortlock DP. Control of BMP gene expression by long-range regulatory elements. Cytokine Growth Factor Rev. 2009;20:509-15.
37. Pachori AS, Custer L, Hansen D, et al. Bone morphogenetic protein 4 mediates myocardial ischemic injury through JNK-dependent signaling pathway. J Mol Cell Cardiol. 2010;48:1255-65.
38. Pegorier S, Campbell GA, Kay AB, Lloyd CM. Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF). Respir Res. 2010;11:85.
39. Sun B, Huo R, Sheng Y, et al. Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy. Hypertension. 2013;61:352-60.
40. Calvieri C, Rubattu S, Volpe M. Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides. J Mol Med (Berl). 2012;90:5-13.
41. Cohen-Solal A, Logeart D, Huang B, et al. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol. 2009;53:2343-8.
42. Franco V, Chen YF, Oparil S, et al. Atrial natriuretic peptide dose-dependently inhibits pressure overload-induced cardiac remodeling. Hypertension. 2004;44:746-50.
43. •• Li P, Wang D, Lucas J, et al. Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res. 2008;102:185-92. This paper details the mechanism of the anti-fibrotic action of the atrial natriuretic peptide. BNP acts by the same ways. So, these peptides are not only diuretic, but essential to limit, if possible, the cardiac fibrosis.
44. Tamura N, Ogawa Y, Chusho H, et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci U S A. 2000;97:4239-44.
45. He JG, Chen YL, Chen BL, et al. B-type natriuretic peptide attenuates cardiac hypertrophy via the transforming growth factor-ss1/smad7 pathway in vivo and in vitro. Clin Exp Pharmacol Physiol. 2010;37:283-9.
46. Caron KM, James LR, Kim HS, et al. A genetically clamped renin transgene for the induction of hypertension. Proc Natl Acad Sci U S A. 2002;99:8248-52.
47. Huby AC, Rastaldi MP, Caron K, et al. Restoration of podocyte structure and improvement of chronic renal disease in transgenic mice overexpressing renin. PLoS One. 2009;4:e6721.
48. Garnier A, Bendall JK, Fuchs S, et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation. 2004;110:1819-25.
49. Di Zhang A, Nguyen Dinh Cat A, Soukaseum C, et al. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension. 2008;52:1060-7.
50. Jaisser F, Swynghedauw B, Delcayre C. The mineralocorticoid receptor in heart: different effects in different cells. Hypertension. 2011;57:679-80.
51. Kuster GM, Kotlyar E, Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005;111:420-7.
52. • Lother A, Berger S, Gilsbach R, et al. Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension. 2011;57:746-54. This paper, and the two following ones, took advantage of invalidation of the MR in mice to decipher the role of this receptor in different cell types. The present paper used fibroblast-specific and cardiomyocyte-specific MR KO; it showed that MR in cardiac myocytes, but not in fibroblasts, protect from cardiac dilatation and failure after chronic pressure overload.
53. •• Rickard AJ, Morgan J, Tesch G, et al. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54:537-43. This paper used macrophage-specific MR KO to demonstrate for the first time that macrophage recruitment is not altered by loss of MR signaling in these cells, and that a novel and significant role is seen for macrophage signaling in the regulation of cardiac fibrosis in the DOCA/salt model.
54. • Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010;120:3350-64. This well documented study myeloid cells-specific knockout of the MR gene to show that myeloid MR is critical in controlling the macrophage polarization. Macrophages from myeloid MR KO mice exhibited a transcription profile of alternative activation. In isolated macrophages, pharmacologic MR blockade has similar effects, thus demonstrating that fibrosis depends of direct effects on the macrophages.
55. Bienvenu LA, Morgan J, Rickard AJ, et al. Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology. 2012;153:3416-25.
56. Funder JW. Aldosterone and mineralocorticoid receptors: a personal reflection. Mol Cell Endocrinol. 2012;350:146-50.
57. Messaoudi S, Gravez B, Tarjus A, et al. Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo. Hypertension. 2013;61:361-7.